EPS for Curis, Inc. (CRIS) Expected At $-0.32

October 13, 2018 - By Peter Erickson

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment decreased to 0.01 in 2018 Q2. Its down 0.85, from 0.86 in 2018Q1. It worsened, as 66 investors sold Curis, Inc. shares while 1 reduced holdings. 1 funds opened positions while 0 raised stakes. 4.06 million shares or 93.46% less from 62.11 million shares in 2018Q1 were reported.
Bain Equity Management Ltd holds 0.01% or 98,344 shares in its portfolio. Meridian Invest Counsel, California-based fund reported 10,000 shares. The New York-based Renaissance Ltd Com has invested 0% in Curis, Inc. (NASDAQ:CRIS).

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.32 EPS on November, 6.They anticipate $0.23 EPS change or 41.82 % from last quarter’s $-0.55 EPS. After having $-0.26 EPS previously, Curis, Inc.’s analysts see 23.08 % EPS growth. The stock increased 1.61% or $0.03 during the last trading session, reaching $1.89. About 146,848 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 85.15% since October 13, 2017 and is downtrending. It has underperformed by 100.77% the S&P500.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis had 2 analyst reports since May 7, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Robert W. Baird on Monday, May 7. The rating was maintained by SunTrust on Thursday, May 31 with “Buy”.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $62.71 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.